NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report report published on Wednesday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Down 2.3 %

NASDAQ NURO opened at $3.45 on Wednesday. NeuroMetrix has a 52 week low of $2.70 and a 52 week high of $7.30. The firm has a 50 day moving average of $3.72 and a two-hundred day moving average of $3.75.

NeuroMetrix (NASDAQ:NURO) last issued its earnings results on Wednesday, May 15th. The medical device company reported ($1.67) earnings per share (EPS) for the quarter. The company had revenue of $1.09 million during the quarter. NeuroMetrix had a negative net margin of 151.51% and a negative return on equity of 39.85%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroMetrix stock. Cerity Partners LLC purchased a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned about 2.80% of NeuroMetrix at the end of the most recent reporting period. 19.40% of the stock is owned by institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.